Addison Whitney Healthcare Group

1 like579 views

Addison Whitney is a leading provider of clinical, communications, and commercialization solutions to the pharmaceutical and life sciences industry. It offers services such as trademark development, market research, visual branding including logo design, and brand strategy. Addison Whitney has a large client list of major pharmaceutical companies as well as emerging and medium-sized clients. It has developed trademarks and brand names for many pharmaceutical products and provided visual identity design for several drug brands.

Addison Whitney is a leading provider of clinical, communications, and commercialization solutions to the pharmaceutical and life sciences industry. They offer services such as trademark development, market research, branding, and strategy. Addison Whitney works with large pharmaceutical clients as well as many emerging and medium-sized clients. Their services include assigning trademarks, brand names, and nonproprietary names to drugs in development.

About Addison Whitneyguest2c957

��

Addison Whitney is a global brand consultancy that has been in business since 1991. They specialize in verbal branding, visual branding, and brand strategy consulting. Addison Whitney works with clients around the world from offices in New York, San Francisco, Munich, Charlotte, and soon Tokyo. They have experience creating and developing brands for many large companies such as Pfizer, Kraft, Procter & Gamble, Cadillac, Campbell's, Microsoft, Wachovia, and Motorola.

2010 Avoca Report Executive SummaryThe Avoca Group

��

The survey examined how clinical research outsourcing relationships between sponsors and service providers are expected to change between 2010-2014. 285 respondents participated, including 109 sponsors and 174 service providers. For sponsors, the top changes made/planned to improve efficiency included better measurement of provider performance, increased use of preferred providerships, and better methods for provider selection. Respondents were asked about drivers of change and how planned changes may impact outsourcing strategies and relationships over this time period.

The Avoca Report Executive Summary: 2011 State of Clinical OutsourcingThe Avoca Group

��

1. There is an association between sponsor size and provider size, with large sponsors generally selecting large, full-service CROs and small sponsors generally selecting smaller, niche providers. 2. This association appears rational, as sponsors of all sizes report highest satisfaction rates when working with mid-sized providers, and small/mid-sized sponsors using large CROs for ≤25% of work are more satisfied than those using them for >25%. 3. While the association exists, satisfaction rates are remarkably similar across sponsor sizes, indicating the "best" provider depends more on individual project needs than sponsor size alone.

Global Trends & Development in Biopharmaceutical Contract Manufacturingmikechan088

��

This document summarizes a presentation on global biopharmaceutical contract manufacturing trends and developments. It discusses market trends such as slowing growth rates in mature markets and higher growth expected in emerging markets. It also covers threats to the industry like lack of capital and increasing regulatory scrutiny. The presentation provides an overview of top biologics companies and contract manufacturing organizations (CMOs) globally. It discusses why customers may choose to work with Indian CMOs due to competitive pricing, quality capabilities, and services offered.

Uphar Specialty Pharma, Ahmedabad, MedicinesIndiaMART InterMESH Limited

��

Uphar Speciality Pharma, established in 1996, is a leading wholesaler, trader, and supplier of a wide range of high-quality medicines, including anti-cancer drugs, HIV/HBV/influenza treatments, and more, sourced from top pharmaceutical companies. The organization is a renowned distributor for eight of the top ten pharma companies in India and maintains a robust sales and distribution network for timely supply. With a focus on quality assurance and safety in packaging, Uphar Speciality Pharma continuously adapts to meet market demands under the guidance of their experienced leadership.

The Landscape of the Biosimilar MarketIndustry Standard Research

��

The document discusses the evolving biosimilar market, highlighting that 21 blockbuster biopharmaceuticals will lose patent protection by 2019, representing a significant market value. It addresses safety concerns related to biosimilars and varying opinions from physicians, pharmacists, and payers on the necessity of clinical trials. Additionally, it notes the recent legislative activity regarding biosimilar notification requirements and record retention, alongside the formation of industry partnerships for biosimilar development.

Biocon Investor Presentation_Q3_FY12Biocon

��

The document discusses Biocon, an Indian biopharmaceutical company. It summarizes Biocon's business structure and holdings, product portfolio including branded formulations, insulin business in India, and strategic partnerships. Notably, Biocon has entered a global commercialization partnership with Pfizer for biosimilar versions of insulin and insulin analogs, which provides upfront and milestone payments totaling $350 million to Biocon.

World Top 50 Pharmaceutical Companies 2009healthcaremanas

��

The pharmaceutical industry saw major consolidation in 2009 through large mergers and acquisitions that reshuffled the rankings of the top pharma companies. Pfizer emerged as the clear number one company after acquiring Wyeth. Merck's merger with Schering-Plough will likely make it the number four company in 2010. Growth through M&A is expected to continue as companies seek new drugs and markets, and the largest pharma companies are approaching $40 billion in annual revenue. Emerging markets are becoming increasingly important as their drug spending catches up to traditional markets.

Lancer Solutions Capabilities Web Versionnickwins

��

Lancer Solutions, LLC is a healthcare business solutions company led by President Lance Nicholls, PharmD. It provides services including healthcare channel strategies, medical education, and pharmacist consultative services. Some example services listed are advisory boards, market research training, event planning, and health screenings. Major pharmaceutical clients mentioned include Amgen, Gilead Sciences, Merck, and Pfizer. Contact information is provided for Lance Nicholls and James O'Connell.

Biocon Investor Presentation (October '11)Biocon

��

The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India where it has the number 1 or 2 market share for several drugs. The presentation outlines Biocon's research and development efforts including its pipeline of novel molecules and biologics in diabetes, oncology and immunology. Key pipeline programs discussed are Itolizumab in Phase 3 for rheumatoid arthritis, IN-105 for oral insulin, and partnerships for strategic alliances.

Biocon Investor Presentation_Oct_2011_H1Biocon

��

The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company based in India. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India, research and development pipeline including potential new molecules and biosimilars. It also outlines strategic partnerships with Pfizer and Mylan to commercialize biosimilar insulins and monoclonal antibodies globally. Financial highlights show strong revenue and profit growth over the past years and in the first half of fiscal year 2012.

Vama Life Care, Mumbai, Pharmaceutical ProductsIndiaMART InterMESH Limited

��

Vama Lifecare is a prominent supplier and exporter of high-quality pharmaceutical drugs and formulations, offering a wide range of products including oncology, nephrology, and neurology drugs. The company emphasizes customer satisfaction, utilizes the latest manufacturing equipment, and adheres to national and international standards. Established in 2010, Vama Lifecare is supported by an experienced team and has a significant global client base.

Pfizer at the 27th Annual J.P. Morgan Healthcare Conferencefinance5

��

This document summarizes a presentation given by Martin Mackay, President of PGRD, at a 2009 JP Morgan conference. The presentation outlines PGRD's strategic goals of aggressively advancing their clinical pipeline, prioritizing their portfolio, becoming a top biotherapeutics company, raising productivity, and pursuing external science. Key achievements from 2008 are noted, including global submissions, approvals, advancing compounds to Phase 3, and business development deals. PGRD's pipeline and goals to start 15-20 Phase 3 trials per year through 2009 are reviewed. Recent disease area focus and exit decisions are presented, as well as an overview of the new Biotherapeutics and Bioinnovation Center and its current pipeline.

Biocon AGM 2012 Presentation July 26, 2012Biocon

��

1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals. 2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities. 3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.

Biocon Investor Presentation_March_2012_9MBiocon

��

The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences: Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.

BiosimilarsSwati Varma

��

The document discusses biopharmaceuticals, focusing on biosimilars which are seen as the future of the medicinal industry, projected to have a significant market growth from 2009 to 2014. It outlines their complex nature, potential cost savings compared to traditional biologics, and the challenges they face, including regulatory hurdles and market competition. Key players in the biosimilars market, particularly in India, are also identified with examples of existing biosimilars and their applications.

Biocon Investor Presentation_Sept_2011_Q1Biocon

��

The document provides an investor presentation for Biocon from September 2011. It summarizes Biocon as an emerging global biopharmaceutical company focused on developing affordable therapies. It discusses Biocon's business structure, product portfolio across areas like diabetes, oncology and biosimilars. The presentation outlines Biocon's research and development pipeline including oral insulin and monoclonal antibody programs. It also describes Biocon's strategic partnerships with companies like Pfizer, Mylan, Amylin and others. Financial highlights show Biocon's revenues growing over 2008-2011 time period with contributions from areas like research services, branded formulations and biosimilars.

Biocon Q4FY12_Investor Presentation_April_2012Biocon

��

The document provides an overview of Biocon's business including: 1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer. 2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships. 3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.

D K R Colorado B I O 07 FinalThink Science Now

��

This document provides an overview of Pfizer's research and development strategies and opportunities for growth through strategic alliances. It discusses Pfizer's global R&D operations and pipeline, challenges in the pharmaceutical industry around shrinking market exclusivity and high drug development attrition rates. It also outlines Pfizer's approaches to alliances like pursuing opportunities aggressively, taking a standard approach, or prioritizing areas of social need. The document emphasizes Pfizer's leadership in biopharmaceutical strategic alliances and investments in external innovation.

Biotech usa 191Didier Touati

��

Podd c no.1366 salles final oct 2011-1ConferenceForum

��

The document provides information about Merck's partnership opportunities conference, including: 1) It discusses Merck's focus on partnerships, with about 64% of its 2010 revenue coming from alliance products and patents. 2) It provides key facts about Merck, such as its global operations, revenue, R&D spending, and pipeline of products in development. 3) It emphasizes Merck's large pipeline and willingness to partner on developing and commercializing drug delivery technologies.

Biocon Investor Presentation Jan 2013Biocon

��

- Biocon is an emerging global biopharmaceutical company focused on developing affordable biologic drugs and biosimilars. - It has several growth segments including small molecules, biosimilars, novel biologics, and research services. - Biocon partners with other companies for drug development and commercialization to leverage its capabilities and for global access. - In 9M FY13, Biocon saw revenue growth of 23% and EBITDA growth driven by performance across business segments.

P. V. Pharma, Ahmedabad, Pharmaceuticals ProductsIndiaMART InterMESH Limited

��

P. V. Pharma, established in 2005 in Ahmedabad, India, is a leading distributor and importer of a wide range of anti-cancer and lifesaving drugs, recognized for their quality and competitive pricing. They source products from reputable Indian and multinational companies and support numerous oncology specialists and hospitals, contributing to an annual turnover of 10 to 20 crore. The company offers a comprehensive product portfolio including drugs from major pharmaceutical companies, focusing on compliance with global quality standards.

9th Biosimilars Conference Brochuresandy_nguyen

��

The 9th Biosimilars Conference held in London from October 5-7, 2011, focused on the clinical, legal, regulatory, and developmental strategies for biosimilars to enhance safety and acceptance in the pharmaceutical industry. Key speakers included experts from various organizations who addressed challenges and advancements related to biosimilars, including regulatory frameworks, economic prospects, and the importance of scientific rigor. The event also featured networking opportunities aimed at fostering collaboration and knowledge sharing among industry leaders.

Investor presentation new 2013 masterAntarespharmatv

��

OTREXUP is a self-administered injectable methotrexate product for rheumatoid arthritis patients. Clinical trials showed OTREXUP was easy for patients to use, caused minimal pain, and delivered systemic exposure comparable to oral methotrexate. With a December 2012 FDA filing, OTREXUP has the potential to address the needs of RA patients by providing a convenient self-injectable option for methotrexate treatment.

9th Biosimilars (2011) PpPiyush Patel

��

The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.

Role of computers in drug design1Ankit Tiwari

��

Computer-aided drug design (CADD) uses computational methods to simulate drug-receptor interactions and has reduced drug research duration by at least 5 years. CADD techniques rely on bioinformatics tools, databases, and applications. Quantitative structure-activity relationship (QSAR) modeling correlates compound structural properties with biological activities and has provided a basis for optimizing ligand molecules to improve activity. CADD approaches include structure-based modeling using protein-ligand docking and ligand-based modeling analyzing statistical relationships between ligand structural groups and biological effects.

�ݺ�ߣ

Addison Whitney Healthcare Group

Recommended

More Related Content

Similar to Addison Whitney Healthcare Group (20)